1-CURE Teaming Profiles
This page is designed to help facilitate connections between prospective proposers, which ARPA-H anticipates will be necessary to achieve the goals of the One Comprehensive Universal Radiotherapy for Everyone (1-CURE) program. Prospective performers are encouraged (but not required) to form teams with varied technical expertise to submit a proposal.
If either you or your organization are interested in teaming, please create a profile via the ARPA-H Solutions Portal linked below. Your details will then be added to this page, which is publicly available.
Please note that by publishing the teaming profiles list, ARPA-H is not endorsing, sponsoring, or otherwise evaluating the qualifications of the individuals or organizations included here. Submissions to the teaming profiles list are reviewed and updated periodically.
1-CURE Teaming Profiles
To narrow the results in the Teaming Profiles List, please use the input below to filter results based on your search term. The list will filter as you type.
| A | AA | AAA | AAA | AAA | AAA | AAA |
| Yong Chen | University of Oklahoma HSC | yong-chen@ou.edu | Oklahoma City, OK | In vivo dose tracking with radiation induced acoustic, flash proton, adaptive proton treatment planning | clinical trial, AI agent enhanced planning | TA2: Abscopal Treatment Planning System |
| Helena de Puig | ExtRNA | Helena@externa.bio | Somerville, MA | Externa Biosciences develops a platform for programmable biologics by expanding the genetic code to incorporate synthetic amino acids into proteins. Using proprietary cell-free translation chemistry, Externa rapidly discovers proteins with novel chemical functions. Preliminary data demonstrate synthetic amino acids that tune binding kinetics and affinity in tumors, enabling improved retention and targeting for radiotherapies. | Externa seeks partners in oncology, radiotherapy, and immunology to advance programmable biologics enabled by synthetic amino acids. We are particularly interested in collaborators with tumor models, radiochemistry expertise, and translational capabilities to evaluate targeting, tumor retention, and immune activation in radiotherapy settings. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Gabriel Sawakuchi | The University of Texas MD Anderson Cancer Center | gsawakuchi@mdanderson.org | Houston, TX | Spatially fractionated radiotherapy to prime anti-tumor immunity. | I am interested to partner with groups that develop pharmacologic approaches to deliver immunotherapy. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Peter Maxim | University Of California, Irvine | pmaxim@uci.edu | Irvine, CA | Our main focus area is FLASH radiotherapy. | We are looking for technologies for the clinical translation of FLASH radiotherapy. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Nicusor Iftimia | PHYSICAL SCIENCES INC. | nicusor.iftimia@gmail.com | Greater Boston Area., MA | Development of various biomedical technologies and instrumentation for disease diagnosis, therapy guidance, and guided therapy. | Clinical and biochemistry partners. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Xuan Wang | Virginia Tech | xuanw@vt.edu | Blacksburg, VA | AI-driven treatment planning system to ensure maximum effectiveness with minimal toxicity. | Looking to join a team led by clinical experts | TA2: Abscopal Treatment Planning System |
| Helena de Puig | ExtRNA | Helena@externa.bio | Somerville, MA, MA | Externa Biosciences develops programmable biologics by expanding the genetic code to incorporate synthetic amino acids into proteins. Using proprietary cell-free translation chemistry, Externa rapidly discovers proteins with new chemical functions. Preliminary data show synthetic amino acids that tune binding kinetics and affinity in tumors, enabling improved retention and targeting for radiotherapy. | Externa seeks partners in oncology, radiotherapy, and immunology to advance programmable biologics enabled by synthetic amino acids. We are particularly interested in collaborators with tumor models, radiochemistry expertise, and translational capabilities to evaluate targeting, tumor retention, and immune activation in radiotherapy settings. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Clemens Grassberger | University of Washington / Fred Hutch | clemensg@uw.edu | Seattle, WA | Our current focus is to investigate the impact of ultra‑high dose‑rate (FLASH) irradiation on lymphocyte depletion overall, but specifically trafficking and activation of effector T cells, and ultimately intratumoral effector T‑cell accumulation. We have two proton FLASH systems (one clinical, one preclinical) and excellent setup to perform preclinical studies and pilot human trials. | A larger abscopal / immunogenicity focused project that our FLASH immunology aspect can be integrated in. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Amit Sawant | University of Maryland | asawant@som.umaryland.edu | Baltimore, MD | proton and electron FLASH radiotherapy, preclinical animal models for FLASH, FLASH dosimetry, AI | SRBs | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Stephen Avery | University of Pennsylvania | steven.avery@pennmedicine.upenn.edu | Philadelphia, PA | Our research focuses on transformative radiation oncology innovations, including Proton FLASH radiotherapy to enable ultra-high dose rate treatments that reduce normal tissue toxicity while maintaining tumor control, and the development of a dynamic spot-scanning proton arc optimization framework to enhance dose conformity, treatment efficiency, and robustness for next-generation precision cancer therapy. | We seek multidisciplinary partners across academia, industry, and government with expertise in advanced therapeutics, imaging, AI/ML, and scalable health technologies. Ideal collaborators bring translational capabilities, engineering innovation, and implementation expertise to accelerate deployment of high-impact, patient-centered solutions in diverse and resource-variable settings. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Corrine Ying Xuan Chua | Houston Methodist Research Institute | ychua@houstonmethodist.org | Houston, TX | My lab develops localized nanomedicine platforms to reprogram immune-desert tumors. We engineered a biodegradable nanofibrous seed that we are advancing into a combination immunotherapy-radiation responsive product, designed to be a single-intervention cancer treatment. | I am looking to team up with Radiation Oncologists skilled in stereotactic radiotherapy to co-design immune-priming protocols. I also would like to team up with Materials Scientists specialized in radio-responsive polymers to optimize our combination immunotherapy-radiation responsive product. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Mark Chen | Duke University Hospital | mark.chen@duke.edu | Durham, NC USA, NC | Delivery of Radionuclides through Phase-Transition Materials; Understanding and Controlling the Mechanism of FLASH radiation | Clinical partners in oncology; Pharma partners | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Avik Som | University of Washington | aviksom@uw.edu | Seattle, WA | We focus on intratumoral immunoadjuvant delivery in combination with radiation therapy for image guidance, retention, and induction. SAIL (Som Advanced Interventions Lab) is a joint partnership of interventional radiology and material science engineering. At UW we also lead the Fred Hutch Cancer Center Intratumoral Program. | We are looking for interested radiotherapy partners, as well as interested de novo agent companies, such as bispecific antibodies, etc. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Amit Khandhar | HDT Bio | amit.khandhar@hdt.bio | Seattle, WA | HDT Bio’s LION nanoparticle is a clinical-stage nucleic acid delivery technology directly aligned with TA1 of the 1-CURE program. LION enables delivery of proprietary RIG-I/TLR3 agonists and replicon RNA encoding genetic adjuvants, activating immune pathways to drive potent anti-tumor responses while simultaneously activating tumor-specific effector T cells. Our first-gen LION platform incorporates MRI contrast agents, combining immunotherapy and ability to perform image-guided radiotherapy. | We are seeking a TA2 partner to build an abscopal treatment planning system that leverages our TA1 LION nanoparticle platform, integrating radiotherapy parameters with SRB-driven immune activation. The partner would apply AI/ML and data integration to model, predict, and optimize systemic anti-tumor responses, enabling effective treatment of both primary tumors and distal metastases. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| John Collins | Biopico Systems Inc | collins@biopico.com | Irvine, CA | Biopico Systems develops human multi-organ microphysiological platforms (OrganRX™) to model immune–tumor interactions and predict immunotherapy outcomes. Our focus includes CAR-T, bispecific antibodies, and ADCs, integrating circulating immune cells with liver, bone marrow, and vascular systems to assess efficacy, cytokine responses, and multi-organ toxicity for translational drug development. | Biopico seeks partners in (1) nanoparticle design and GMP manufacturing, (2) FLASH radiotherapy physics and delivery, (3) AI/ML for treatment planning and digital twin modeling, and (4) clinical oncology for translational validation. Ideal collaborators bring expertise in immunoadjuvants, imaging, and patient-relevant data to integrate with our human multi-organ OrganRX™ platform. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| David Zaharoff | NC State | dazaharo@ncsu.edu | Raleigh, NC | Delivery systems for localized immunotherapy | omics, bioinformatics | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Chang Chang | UCSD | chang2@ucsd.edu | San Diego, CA | Our group develops human-centered, AI-enabled systems for autonomous radiotherapy treatment planning. We’ve published our framework in Med Phys and Red Journal combining deep learning, dose prediction, automated objective adjustment, and iterative optimization. This foundation aligns with TA2, and its optimization engine, automation logic, and user-facing architecture can be readily extended into an ATPS by incorporating immune-response models, QA, visualization, and hypothesis testing. | I am seeking TA1 partners with expertise in immunogenic nanoparticles, smart radiotherapy biomaterials, and experimental immuno-oncology. I am especially interested in collaborators who can design image-visible, immune-stimulating biomaterials with controlled delivery and generate data for ATPS validation. My group would lead autonomous planning and computational integration, while TA1 partners would lead biomaterial innovation and experimental testing. | TA2: Abscopal Treatment Planning System |
| Issam El Naqa | H. Lee Moffitt Cancer Center & Research Institute | issam.elnaqa@moffitt.org | Tampa, FL | Immunoradiotherapy, FLASH irradiation, in vivo dosimetry, artificial intelligence, outcome modeling | Immunoradiotherapy, FLASH irradiation, in vivo dosimetry, artificial intelligence, outcome modeling | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Scott Floyd | Duke University | scott.floyd@duke.edu | Durham, NC | We are a university-based research group interested in very high energy electron FLASH radiotherapy. Our multi-disciplinary research group spans particle and accelerator physics, medical physics and dosimetry, radiobiology and clinical radiation oncology. We developed a unique very high energy electron beam line with mean dose rates of up to 35 million Gray per second (our fastest to date). This extremely high dose rate improves normal tissue tolerance, immune response and tumor control. | We are looking for engineering expertise in both accelerator design and control systems to help translate our research beam to a compact, clinical-deployment ready unit to enable clinical trials. | TA2: Abscopal Treatment Planning System |
| Ketan Ghaghada | Baylor College of Medicine | ghaghada@bcm.edu | Baylor College of Medicine / Texas Children's Hospital, Houston TX, TX | Our research focus and expertise is in the development and translation of nanoparticle-based agents for use in CT imaging - this could potentially aid in tumor painting and effective RT planning. Furthermore, the nanoparticles could be modified to also deliver therapeutics, thus serving as theranostic agents. | Potential teaming partners would be experts in RT planning and to leverage nanoparticle-contrast enhanced CT of tumor in combination with AI approaches for optimizing RT. Additionally, we could collaborate with researchers with complementary expertise to enable effective delivery of immunomodulators to desired cells types using nanoparticles that could potentially lead to abscopal effects and treatment of metastatic lesions. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Seth Gammon | UT MD Anderson Cancer Center | stgammon@mdanderson.org | Houston, TX | Development of single chain protein therapeutics for MD preprogramming of the tumor immune micro-environment | a metal nanoparticle system that can aid in both delivery and detection by CT and MRI | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Igor Shuryak | Columbia University, Center for Radiological Research | is144@cumc.columbia.edu | New York, NY | Our group integrates mechanistic radiobiological modeling (linear-quadratic, BED, TCP/NTCP) with causal machine learning (Double ML, causal forests, TMLE) applied to large oncology cohorts. Current projects include radioligand therapy precision dosimetry, FLASH-RT dose-response modeling, and AI-driven treatment outcome prediction. We specialize in translating complex biological mechanisms into clinically actionable, causally interpretable predictive frameworks. | We seek collaborators with expertise in smart radiotherapy biomaterials (SRBs), nanomedicine, or tumor immunology to complement our quantitative modeling capabilities. Ideal partners bring experimental or clinical infrastructure for FLASH-RT delivery and immune response characterization, enabling integration with our AI-driven treatment planning and causal dose-response optimization platform. | TA2: Abscopal Treatment Planning System |
| Jessica Larsen | Clemson University | larsenj@clemson.edu | Clemson, SC | Radiation-responsive complex coacervates to deliver radiation-enhancing RNAs | Cancer or RNAs expertise | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Conan Wang | The University of Queensland | c.wang@imb.uq.edu.au | Brisbane, Australia | Protein and peptide engineering. Design of targeting biomolecules. | Radiochemists. Radiobiologists. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Judee Sharon | KuriBio | judee@kuribio.com | Berkeley, CA | KuriBio is developing a liposomal targeting platform for cell-specific delivery across diverse tissues. Our particles use combinatorial surface ligands and can carry multiple payload types, including contrast agents, radiotherapies, proteins, DNA, and RNA. The platform improves targeting specificity, reduces off-target toxicity, and enhances the safety profile for cancer therapies. | We seek partners with payload, radiotherapy, and adjuvant expertise. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Sahaja Acharya | Johns Hopkins | sachary7@jhmi.edu | Baltimore, MD | enabling proton FLASH for clinical trials, developing smart radiotherapy biomaterials, developing treatment planning system for proton FLASH | industry partner | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Tobias Funk | Triple Ring Technologies | tfunk@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products in medtech and life sciences. Our interdisciplinary team (30% PhDs) excels in advancing technologies to FDA approval while working with academic partners. We won ARPA-H awards as sub and multiparty. We offer capabilities in simulating and measuring dose in phantoms and anatomical models, developing FDA-approved treatment planning algorithms, software and GUI development, and project management. ISO 13485 cert. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, as well as complex system integration. We are looking for teaming partners that could use our expertise in radiation therapy while navigating the FDA regulatory pathway. We have acted as primary, subcontractor, or vendor on previous submissions. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Charles Limoli | University of California, Irvine | climoli@uci.edu | Irvine, CA | Advanced radiotherapy platforms with an emphasis on FLASH and brain tumors. | Expertise in AI treatment planning | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Ibrahim Oraiqat | Radiation | ibrahim.oraiqat@moffitt.org | Tampa, FL | FLASH Radiotherapy in two major areas: 1) we have developed a 3D real-time dosimetry system for FLASH radiotherapy to give instantaneous feedback to dose measurement and localization with respect to anatomy (for real time gating). 2) The study of how FLASH radiotherapy affects immune response to cancer therapy | We would look for additional partners that specialize in treatment planning optimization (e.g., LET optimization), ultrasound/photoacoustic reconstruction, advanced optical imaging. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Alessandro Grattoni | Houston Methodist Research Institute | agrattoni@houstonmethodist.org | Houston, TX | Multifunctional radiopaque degradable polymeric intratumoral nanofluidic seeds for sustained delivery of immunotherapeutics and image guidance for radiotherapy. Analysis of safety, efficacy, abscopal effect and local and systemic biodistribution of immunotherapeutics released from the seed in pancreatic cancer, triple negative breast cancer, and lung cancer and clinical phase 1 trial of the intratumoral seed technology in triple negative breast cancer. | Complementary expertise and access to clinical grade immunotherapeutics | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Mansoor Ahmed | Albert Einstein College of Medicine | mansoor.ahmed@einsteinmed.edu | Bronx, New York, NY | Spatial-temporal dose heterogeneity present in GRID/LATTICE RT, LDFRT and FLASH-RT to reprogram the TME. The SFRT peak-valley (GTV- Bystander treatment volume) delivery remodels vasculature with systemic immune responses, and LDFRT potentiates immune ICB. There is growing preclinical evidence that FLASH-RT intersects with our on SFRT. It is possible that combining FLASH with SFRT could improve normal tissue protection while enhancing tumor-directed abscopal responses in several solid tumors. | We seek collaboration to translate SFRT (GRID/LATTICE), FLASH-RT, and LDFRT into randomized trials, leveraging SFRT-induced tumor immune modulation across solid tumors. This requires partners with novel radiation oncology, medical physics and dosimetric expertise for rigorous consensus-based trial design, in collaboration with immune-oncology groups and NCI-ETCTN/NCTN members capable of supporting early phase and definitive combination trial infrastructure. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Siyang Zheng | Carnegie Mellon University | siyangz@andrew.cmu.edu | Pittsburgh, PA | Our research focuses on biomaterials-enabled drug delivery and liquid biopsy technologies, including MOF-based systems and extracellular vesicles. We develop platforms that modulate tumor redox balance, amplify oxidative stress, and regulate immune-relevant pathways. A current direction is integrating these biomaterials with radiotherapy to convert transient radiation-induced signals into sustained and spatially controlled therapeutic responses. | We are seeking collaborators with expertise in radiotherapy, including FLASH-RT, radiation biology, and treatment planning. We are particularly interested in partners who can integrate biomaterials with RT to study oxidative stress, immune activation, and systemic responses. Capabilities in preclinical models and translational radiotherapy studies are highly desirable. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Roger Johnson | Medical College of Wisconsin | rjohnson@mcw.edu | Milwaukee, WI | TA1: Published studies on gold and lipid nanoparticle radiosensitizers with CT and MRI image contrast. Pre-clinical models and innovative clinical trials in pancreatic adenocarcinoma and other cancers. TA2: Working novel radiation treatment planning software incorporating immunologic parameters of radiation sensitivity, readily adaptable to model abscopal interactions, FLASH, and nanoparticle radiosensitization. Pre-clinical and clinical proton FLASH capability (Mevion with FLASH kit). | Groups with a) deep GLP and GMP capability needed for nanoparticle scale-up and IND-enabling studies through early phase clinical trial implementation; b) state-of-the-art immune adjuvants including nanoparticle formulations and validated immunomonitoring assays; and c) a seasoned verification and validation team experienced in regulatory-grade clinical implementation of treatment planning software. We are eager to engage industry partners with complementary expertise in any of these capacities. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Amit Joshi | Medical College of Wisconsin | ajoshi@mcw.edu | Milwaukee, WI, WI | TA1: Published studies on gold and lipid nanoparticle radiosensitizers with CT and MRI image contrast. Pre-clinical models and innovative clinical trials in pancreatic adenocarcinoma and other cancers. TA2: Working novel radiation treatment planning software incorporating immunologic parameters of radiation sensitivity, readily adaptable to model abscopal interactions, FLASH, and nanoparticle radiosensitization. Pre-clinical and clinical proton FLASH capability (Mevion with FLASH kit). | Groups with a) deep GLP and GMP capability needed for nanoparticle scale-up and IND-enabling studies through early phase clinical trial implementation; b) state-of-the-art immune adjuvants including nanoparticle formulations and validated immunomonitoring assays; and c) a seasoned verification and validation team experienced in regulatory-grade clinical implementation of treatment planning software. We are eager to engage industry partners with complementary expertise in any of these capacities. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Patrick Stayton | University of Washington | stayton@uw.edu | Seattle, WA | Radiotherapy induces immunogenic tumor cell death, releasing tumor antigens and cytosolic DNA that activate cGAS–STING signaling, but responses are often insufficient due to limited amplification and immunosuppression. Our group developsa nanoparticle immune modulators that enhance activation ofdendritic cells, type I interferon, cross-presentation, and CD8⁺ T-cell priming, promoting T cell–inflamed tumors and enabling systemic abscopal antitumor effects. | Radiation therapy, sophisticated animal models, PET imaging of pathway activation | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Zeev Harel | Magneto-Cure Inc. | zeev.h@magneto-cure.com | We are located in Kfar-Saba (Israel) but will relocate to Huston TX, TX | Magneto-Cure’s Magnetocytolysis platform introduces a novel therapeutic approach that uses paramagnetic nanoparticles (PNP) together with a low-energy alternating magnetic field (AMF) to selectively eliminate cancer cells. | We'll collaborate with MD Anderson Cancer Center and UTH (both in Huston). | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Chandan Guha | Albert Einstein College of Medicine | cguhamd@gmail.com | Bronx, NY | Centered on bioconvergent health, we integrate cancer biology, radiation science, immunotherapy, and data science to advance precision oncology. Our work spans cancer vaccines, biomarkers, imaging, and tumor microenvironment modulation using AI and preclinical models. We explore FLASH radiotherapy and particle biology to develop drug–device combinations with radiation and ultrasound, enhancing immune responses and improving durable outcomes across diverse patient populations. | Seeking collaborative partners with complementary strengths in translational science, engineering and clinical innovation. Teams with strengths in nano-immuno oncology, advanced imaging and data science/AI – with a demonstrated ability to move quickly into the clinic - are ideal. We look for partners that are creative, agile, and dedicated to attacking challenging problems in cancer care with novel, patient-centered solutions. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Avraham Halbreich | Magneto-Cure Inc. | avraham.h@magneto-cure.com | 24 HAEMEK St., KFAR SABA, ISRAEL | In Magneto-Cure’s Magnetocytolysis, ligand-bound paramagnetic nanoparticles are delivered to tumor. The innocuous theranostic agents are traced by imaging and activated by alternating magnetic field to ablate it in a Néel mechanism w/o heating, toxins, ionizing radiation or side effects. Patients return rapidly to routine and control & repeats at short intervals. Different cancers can be treated by choice of ligand. The stable reagent and simple field applicator can be deployed to basic clinics. | We team up with Hebrew U Med School, Jerusalem – Profs Z Yaari, MS Da Silva - (particle synthesis, cell culture validation, biochemical & physical mechanistic study & FMR characterization), U of Texas Health, Houston TX – Prof S Krishnan - (pharmacokinetics & pharmacodynamics & preclinical characterization and efficacy in animal models) & MDACC, Houston TX – Prof M Salehpour - ( validation of alternating magnetic field applicator & imaging protocols by MRI and MPI) | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Shuming Nie | University of Illinois at Urbana-Champaign | snie2008@gmail.com | Urbana Champaign, IL | Radio ligands, cancer immunotherapy, image-guided cancer surgery, and AI-surgery and planning. | Medical and radiation oncologists. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Liyong Lin | Emory University | llin30@emory.edu | Atlanta, GA | Proton Therapy FLASH treatment planning system with LET optimization with potential to drive abscopal effect | Nano particles. We are good at TPS, delivery and immune response but happy to collaborate | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Needa Brown | University of Central Florida | needa.brown@ucf.edu | Orlando, FL | The NanoBio lab at University of Central Florida focuses on the formulation of nanomaterials and biomaterials as drug delivery systems for cancer, with a special focus on breast, ovarian, and lung. We are actively developing low-cost, sustained release implants for activation of innate immunotherapy treating both local and systemic sites. We design biomaterials solutions by leveraging inherent materials-biological interactions to reactive cold tumor sites into hot, immunogenic regions. | Immunologist and medical physicist | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Prakash Nallathamby | Berthiaume Institute for Precision Health / University of Notre Dame | prakash.d.Nallathamby.1@nd.edu | Notre Dame, IN | We engineered multifunctional smart radiotherapy biomaterials (SRBs). By utilizing magnetoelectric silica nanoparticles (MagSiNs), we can embed therapeutic radioligands within the silica shell and conjugate immunoadjuvants to the surface. This creates precise, magnetolectrically localized, image-guided SRBs capable of sustained delivery to eradicate localized, metastatic, and radiotherapy-resistant cancers. In vitro data (10.3390/ph15101216). In vivo (unpublished) | We have the design, synthesis, and manufacturing expertise to develop these cancer-localizing, modularly assembled therapeutic MRI/radiocontrast probes. We need help with AI-driven treatment planning system and image guided therapy. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Matt Sigmund | SIA/LBG | Msigmund@lathambiopharm.com | Elkridge, MD | Sia/LBG provides full-spectrum support for federal funding, specializing in proposal development and post-award execution. Our subject matter experts in digital health bring deep domain knowledge in areas like health IT, AI-driven diagnostics, and data interoperability. We craft compliant, compelling proposals tailored to funder priorities and guide post-award reporting, stakeholder engagement, and program delivery to ensure lasting success. | SIA/LBG is seeking to partner with organizations developing innovative, breakthrough technologies with the potential to satisfy program requirements and that are interested in engaging an experienced partner to enhance proposal development and ensure disciplined, compliant post-award program execution. | TA2: Abscopal Treatment Planning System |
| Xuanfeng Ding | Corewell East, William Beaumont University Hospital | xuanfeng.ding@corewellhealth.org | Royal Oak, MI | William Beaumont University Hospital, Proton Therapy Center has a world-renowned clinical and research physics focused on the innovative proton radiotherapy including proton arc therapy, FLASH, quality assurance and adaptive therapy. We have developed the world first proton arc therapy system which is expected to be FDA approval in 2027. The team is currently supported by NIH (first TPS for Arc) and drive this technology to the routine clinic which has potential to enhance the abscopal effect. | We have a long term partnership with Upenn (Dr. Steven Avery) and have been discussing the potential opportunity to build a treatment planning system to support the multi-modality treatment including FLASH, Arc and immunotherapy. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Eric Mastria | Duke University | eric.mastria@duke.edu | Durham, NC | Elastin-like polypeptides (ELPs) that transition to a gel-like depot upon intatumoral injection for local retention. The ELPs can be co-expressed with immunotimulatory proteins, and/or conjugated to radionuclides as a brachytherapy treatment. | AI expertise | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Silvia Minardi | University of Chicago | sminardi@uchicago.edu | Chicago, IL | We can cover all requested components at the preclinical level, have ongoing clinical trials in multiple cancer types | A company that can produce our nanoparticles for the clinical trial that we would propose. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Daniel Badali | Triple Ring Technologies | dbadali@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products in medtech and life sciences. Our interdisciplinary team (30% PhDs) excels in advancing technologies to FDA approval while working with academic partners. We won ARPA-H awards as sub and multiparty. We offer capabilities in simulating and measuring dose in phantoms and anatomical models, developing FDA-approved treatment planning algorithms, software and GUI development, and project management. ISO 13485 cert. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, as well as complex system integration. We are looking for teaming partners that could use our expertise in radiation therapy while navigating the FDA regulatory pathway. We have acted as primary, subcontractor, or vendor on previous submissions. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Xueding Wang | University of Michigan | xdwang@umich.edu | Ann Arbor, MI | Our team including the researchers at the University of Michigan and the Moffitt Cancer Center is developing a novel imaging technology, namely ionizing radiation acoustic imaging (iRAI), for mapping the dose delivery in vivo during radiation therapy which includes both FLASH radiation therapy and conventional dose radiation therapy. | We are happy to partner with any other teams looking for expertise in FLASH radiation dose mapping in vivo, which is essential for understanding the immune and other treatment responses to FLASH radiation therapy. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Yongbin Liu | Houston Methodist Research Institute | yliu2@houstonmethodist.org | Houston, TX | We develop transformative smart drug delivery platforms, including implants loaded with cancer immunotherapeutics that enable remotely triggered, on-demand release. By integrating advanced biomaterials, immunomodulation, and translational oncology, our work aims to overcome tumor immune suppression and enable rapid, precise, and effective cancer therapy across diverse solid tumors. | We seek interdisciplinary partners with expertise in AI-driven treatment planning, advanced manufacturing, CMC, and clinical oncology. Ideal collaborators can accelerate translation of smart drug delivery and radiotherapy technologies, providing preclinical and clinical insights to advance high-risk, high-reward cancer therapies. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Matthew De Remer | Mission Driven Tech | matt@engineeredpd.com | Stony Brook, NY | Improving patient outcomes with a novel High Dose Rate (HDR) brachytherapy applicator | We don't offer the whole package that this grant seems to be looking for. A treatment planning partner and other partners that can fill gaps would be great. | TA2: Abscopal Treatment Planning System |
| Mohammad Rezaee | Johns Hopkins University | mrezaee1@jh.edu | Baltimore, MD | Preclinical FLASH Radiotherapy using kilo voltage x-rays | Translation of FLASH RT into clinic | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Sandra Demaria | Weill Cornell Medicine - NY | szd3005@med.cornell.edu | New York, NY | Cancer immunotherapy, combinations of radiation therapy and immunotherapy | FLASH-RT | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Sayeda Yasmin-Karim | DFCI | sayeda_yasmin-karim@DFCI.Harvard.edu | Boston, MA | aerosol drug delivery for immuno-chemotherapy and radiation therapy to generate abscopal effect for systemic cancer treatment. | Potential skill in aerosol drug development | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Zachary Reitman | Duke University School of Medicine | zjr@duke.edu | Durham, NC | I am a radiation oncologist-scientist at Duke. I have expertise in the HIGS-FLASH beam line that can deliver ultra high dose rate very high energy electrons (VHEE) with a very high intrapulse dose rate (IDR). I also have an interest in radioresistance factors to enhance the efficacy of cellular immunotherapies when combined with radiation therapy. I have clinical expertise in CNS radiation oncology. | Interested in teams that can leverage our expertise in CNS radiation oncology, pediatric radiation oncology, cell therapy - radiation combinations, and/or FLASH radiotherapy (particularly the unique HIGS-FLASH beam at Duke, along with Dr. Mark Oldham, Dr. Ying Wu, and Dr. Scott Floyd). | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Mark Oldham | Select One | mark.oldham@duke.edu | durham, NC | FLASH radiation therapy with extremely high dose rates and very high energy electron beams | collaborators with smart materials need evaluating in high energy FLASH electron beams | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Ivan Kempson | Adelaide University | Ivan.Kempson@adelaide.edu.au | Adelaide, Australia | - Nanoparticle and adjuvant radiosensitization - Experience with nanoparticle/nanomaterial radiosensitization under 6 MV, kV, proton FLASH and brachytherapy sources - Nano-adjuvant immunomodulation in murine metastatic cancer models - Single cell TME characterization - 6 MV linac multi-fraction irradiation/phantoms/dosimetry - Novel DNA DSB assays, radiobiology and repair inhibitors - Nanoparticle and material synthesis, conjugation & characterization - Proteomics and protein corona workflows | - Immunology - Biostatistics - Single cell sequencing - Pre-clinical models | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Hua Wang | University of Illinois at Urbana-Champaign | huawang3@illinois.edu | Urbana, IL | We have multiple biomaterial platforms that enable controlled release of immunoadjuvants and a good knowledge of which immunoadjuvants to use in different contexts. We also have immune cell homing biomaterial platforms that enable in situ recruitment and modulation of dendritic cells. | Expertise in the development of AI-driven treatment planning system | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Narayan Sahoo | UT MD Anderson Cancer Center | nsahoo@mdanderson.org | Houston, TX | Combined ablative focal high LET ultrahigh dose rate proton therapy combined with nanoparticles and immune therapy to control primary and metastatic tumors | Design of suitable nanoparticles to carry immunogenic agents to enhance body's immune response with proton therapy, development of functional and molecular imaging to identify the targets for focal ablation, determination of suitable immune therapy drugs, and development of suitable biomarkers to monitor the therapy response and adaptation. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Amberlie Clutterbuck | The Emmes Company | aclutterbuck@emmes.com | Rockville, MD | Emmes is a specialty technology and AI-enabled clinical research organization (CRO) with 50 years experience in phase I to IV oncology clinical trials. We have extensive work with commercial, government, non-profit, and academic clients providing full service support, including design and study start up to FDA submission. Our experience includes breast, prostate, liver, and GI cancers. | We are looking to provide clinical trial support in the areas of biostatistics, bioinformatics, study design and start up, protocol development, clinical trial management and monitoring, and medical writing, and patient and site recruitment. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Suzie Pun | University of Washington | spun@uw.edu | Seattle, WA | Tumor targeted delivery and delivery of immunoadjuvants | Radiotherapy and FLASH RT expertise | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Ayse Gurses | JHU | agurses1@jhmi.edu | Baltimore, MD | The Center for Human Factors in Healthcare at Johns Hopkins Armstrong Institute conducts research on human centered design, usability, acceptability, trust to technology, cognitive engineering, implementation science and safe integration of AI in healthcare workflows. Our work combines field studies, cognitive task analysis, and systems engineering to inform the design and evaluation of usable , trustworthy AI-enabled technologies in health care. | We are looking for supporting applications that need expertise in human or user-centered design, usability, acceptability of technology, interface design, human technology interaction, sociotechnical systems approach, implementation science in health care. | TA2: Abscopal Treatment Planning System |
| Cupid Chan | Pistevo Decision | cchan@pistevodecision.com | Herndo, VA | Pistevo Decision provides the AI decision-integrity and governance substrate for 1-CURE's Abscopal Treatment Planning System (TA2). Based on our Veraxum platform's neuro-symbolic GraphRAG, we deliver uncertainty-aware abscopal response prediction, multi-objective FLASH-RT/SRB optimization, and bitemporal data provenance for FDA PCCP-aligned model governance. Every ATPS recommendation is traceable, auditable, and clinician-interpretable via explainable reasoning chains. | Seeking: (1) FLASH-RT clinical physics team with proton or electron FLASH hardware and commissioning QA expertise; (2) nanoparticle SRB engineering group with immunoadjuvant loading, CT/MRI contrast, and GMP translation path; (3) NCI cancer center with bilateral tumor models, immune monitoring, and Phase I/II trial infrastructure; (4) regulatory PDL experienced in combination product IND/IDE and FDA SaMD pathways. | TA2: Abscopal Treatment Planning System |
| Robert Mutter | Mayo Clinic | mutter.robert@mayo.edu | Rochester, MN | We are the first worldwide to treat cancer patients with minibeam radiotherapy (MBRT) using a low-cost, widely available orthovoltage unit. Clinical data (NCT07062003) show rapid tumor regression and minimal toxicity, even at dose levels previously considered prohibitive. In 5 patients, we observed abscopal responses. To extend MBRT to deeper tumors, we have developed and commissioned proton MBRT. Our central hypothesis is that MBRT induces distinct responses that improve the therapeutic ratio. | Our preliminary preclinical and clinical data demonstrate that low-cost MBRT enables unprecedented dose escalation and provides greater systemic immune protection compared with conventional RT. Further, normal tissue toxicity is reduced. We are seeking collaborators with expertise in nanoparticle smart radiotherapy biomaterials that may further enhance these effects, as well as in AI and machine learning to better predict those likely to benefit from novel MBRT combinatorial approaches. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Patrick Stayton | University of Washington | stayton@uw.edu | Seattle, WA | targeted radiotherapy plus targeted immunetherapeutic platform | complementary radiotherapy expertise | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Yashas Kannan | PentaBind | Yashas.Kannan@pentabind.com | Scale Space, 58 Wood Ln, London W12 7RZ, United Kingdom | PentaBind is an AI-aptamer therapeutics company developing tuneable radiopharmaceuticals to enhance precision radiotherapy. Aptamers are high-affinity, programmable nucleic acids that enable selective targeting of cancer neoepitopes, deep tumour penetration, and precise radionuclide delivery. Our platform integrates deep learning with experimental validation to rapidly generate high-affinity binders with controllable pharmacokinetics, supporting scalable, next-generation radiotherapy approaches. | PentaBind is seeking interdisciplinary partners to build an integrated radiotherapy platform aligned with the 1-CURE vision. We are particularly interested in collaborators in radiochemistry, smart biomaterials, AI-driven treatment planning, clinical oncology, and manufacturing. Ideal partners will work with us to integrate targeting, payload delivery and system-level optimisation into clinically translatable, accessible cancer therapies. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Andrew Wang | UT Southwestern | andyzhuangwang@gmail.com | Dallas, TX | I have developed a nanoparticle therapeutic that can increase the abscopal response. It is currently in Phase I investigation. Preliminary data shows excellent safety profile with therapeutic signal. | I am looking for a FLASH planning partner | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Morgan Stykel | Absco Therapeutics | morgan@abscotx.com | Allston, MA | Our work centers on smart biomaterials for image-guided, ultra-sustained immunoadjuvant delivery to drive robust local immune activation and antigen-specific immune education with minimal systemic toxicity. We are exploring the integration of our TLR-agonist-delivering thermogelling polymer platform with FLASH-RT to eliminate primary tumors and create a robust abscopal effect, providing a scalable next-generation cancer treatment that achieves the promise of targeted immunotherapies. | We seek partners in FLASH-RT, AI-driven treatment planning, and immuno-oncology to enable reliable abscopal responses and accelerate scalable cancer therapies. With the right team, we aim to rapidly advance a unified, curative radiotherapy approach. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Sami Tantawi | Arizona State University | stantawi@asu.edu | Tempe, AZ | At Arizona State University (ASU), we lead world-class research in accelerator technology. Our program has developed one of the most compact linear accelerators available, with capabilities that include generating very high energy electrons (VHEE), producing narrow-band X-rays via Compton scattering, and delivering ultra-high dose-rate X-rays through innovative, high-efficiency accelerator designs. | We are interested in collaborating with groups seeking practical solutions for FLASH radiotherapy, as well as researchers in chemistry and related fields who can benefit from our narrow-band X-ray source technology. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Moustafa Mabrouk | Adelaide Uni | moustafa.mabrouk@adelaide.edu.au | Adelaide, Australia | We create immunogenic nanoparticles with enhanced active diffusion and radio sensitization capabilities | Mouse model | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Guy Garty | RARAF - Columbia University | gyg2101@cumc.columbia.edu | Irvington, NY | The Radiological Research Accelerator Facility at Columbia University provides pre clinical and ex-vivo irradiation with FLASH protons and electrons, ion beams and neutrons. | We are looking for users to utilize our advanced irradiation platforms | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Kai Ding | Johns Hopkins University | kding1@jh.edu | Baltimore, MD | The Johns Hopkins Smart Biomaterial & Image-Guided Radiotherapy Lab develops multifunctional immune-activating smart radiotherapy biomaterials (SRBs) integrated with FLASH radiotherapy to enable precise image-guided targeting and sustained immunoadjuvant delivery. Our work focuses on inducing robust systemic and abscopal anti-tumor responses using nanoparticle-enabled platforms to treat both local and metastatic cancers. Representative publication: https://www.mdpi.com/1999-4923/17/10/1273 | We seek interdisciplinary partners in biomaterials and nanoparticle engineering for immune-activating SRBs, tumor immunology for mechanistic validation, and AI/physics teams to develop abscopal treatment planning systems (ATPS) integrated with FLASH radiotherapy, enabling curative, systemic cancer treatment. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Keith Cengel | University of Pennsylvania | keith.cengel@pennmedicine.upenn.edu | Philadelphia, PA | Our research team has multiple strengths with ongoing experience in proton FLASH radiotherapy mechanisms, normal tissue radiation protection, integration of physical dose and physiologic outcomes, development and testing of novel radiotherapy and dosimetry systems, development of novel immunologic strategies with radiation, therapeutic nanoparticle design and development, translation of novel radiotherapy and immunotherapy approaches into canine and human radiotherapy trials | collaborative partners with complementary expertise in FLASH (particularly electron and photon modalities), development and testing of novel radiotherapy and dosimetry systems/methods, nanoparticle design and testing, immunotherapy and radiotherapy/immunotherapy clinical trials | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Ashutosh Chilkoti | Duke University | chilkoti@duke.edu | Durham, NC, USA, NC | Expertise in protein engineering of immunomodulatory biomolecules, development of nanoparticles and injectable depots for their sustained intratumoral delivery, and injectable brachytherapy. | Treatment planning and AI models | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| William Hall | Medical College of Wisconsin | whall@mcw.edu | Milwaukee, WI | TA1: Published studies on gold and lipid nanoparticle radiosensitizers with CT and MRI image contrast. Pre-clinical models and innovative clinical trials in pancreatic adenocarcinoma and other cancers. TA2: Working novel radiation treatment planning software incorporating immunologic parameters of radiation sensitivity, readily adaptable to model abscopal interactions, FLASH, and nanoparticle radiosensitization. Pre-clinical and clinical proton FLASH capability (Mevion with FLASH kit). | Groups with a) deep GLP and GMP capability needed for nanoparticle scale-up and IND-enabling studies through early phase clinical trial implementation; b) state-of-the-art immune adjuvants including nanoparticle formulations and validated immunomonitoring assays; and c) a seasoned verification and validation team experienced in regulatory-grade clinical implementation of treatment planning software. We are eager to engage industry partners with complementary expertise in any of these capacities. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Thomas Mackie | Leo Cancer Care | trmackie@wisc.edu | Madison, WI | Leo Cancer Care has developed upright radiotherapy to make particle therapy more affordable and to enable patients to be set up faster, to reduce breathing motion and lower cost of external beam therapy include FLASH radiotherapy. | University radiotherapy programs such as Stanford, University of Pennsylvian, and MD Anderson and accelerator companies like TibaRay and RaySearch | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Michael Lerch | Wollongong University | mlerch@uow.edu.au | Wollongong, NSW, Australia | The Centre for Medical Radiation Physics, University of Wollongong specializes in design and development of software and hardware systems for safe and more effective cancer treatment delivery. Current research focus areas include biocompatible nano-structured particle developments for improving imaging contrast in diagnosis as well as dose enhancement in treatment; radiation transport simulations for treatment modelling and planning; electronic detection systems for treatment quality assurance. | Our organization is looking for potential teaming partners that can: 1) Independently test and validate these systems in various clinical scenarios. 2) Provide novel platforms that require the utilization of our specialties and expertise. Of particular interest is synergistic clinical outcomes created by combination cancer therapy and neoadjuvant therapy in otherwise treatment resistant cancers. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Yuri Mackeyev | University of Texas Houston Health Science Center | yuri.mackeyev@uth.tmc.edu | Houston, TX, TX | UTHealth Houston is actively involved in clinical trials that have led to the discovery of new treatments and have been pivotal in advancing healthcare. Pulmonary and Critical Care Medicine: Research in this area includes studies on hypoxia signaling during alveolar inflammation and the interdependence of circadian rhythm signaling and HIFs during cardiac injury. | UTHealth Houston seeks collaborative partners across healthcare, research, education, and community organizations to advance health initiatives, clinical trials, and educational programs. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| June Lee, MD, PhD | National Society of Medical Scientists (NSMS) | Dr.JuneLee@nsmsusa.org | Bethesda, MD | NSMS Team C specializes in bridging clinical oncology with advanced AI. Our focus is developing predictive models for the abscopal effect to optimize radiotherapy dose and irradiation field size. We possess deep expertise in clinical workflow definition for radiation/medical oncology, systemic immunotherapy integration, and AI-driven healthcare architecture. We focus on transforming complex treatment parameters into scalable, clinician-friendly planning systems. | We seek partners specializing in TA1 (Immunogenic Nanoparticle Smart Radiotherapy Biomaterials). Specifically, we are looking for experts in nanoparticle engineering, click chemistry, and immunoadjuvant development. Our goal is to integrate our AI-driven Abscopal Treatment Planning System (TA2) and clinical validation expertise with a team capable of producing the physical SRBs required for a comprehensive | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Dennis Zimmermann | Matrisome Bio | dennis@matrisomebio.com | Cambridge, MA, MA | Where others see a barrier, we see a therapeutic opportunity! We are tackling the largest unmet need in oncology: metastatic solid tumors that often evade traditional cell-targeted therapies. Matrisome Bio is pioneering a new class of therapies that deliver radioactive payloads directly to the extracellular matrix of tumors and metastases while sparing normal tissues, achieving unmatched precision and therapeutic index. | We would seek partner teams that have deep expertise in the following areas to make possible 1-CURE's goal of developing a single, rapid, low-cost, and accessible radiotherapy approach to battle all types of cancer, including local, metastatic and RT-resistant cancers: - Tumor-stroma immunobiology experts focused on mechanisms surrounding targeted engagement of the immune system. - Nanoparticle biomaterial drug expertise - Medicinal chemistry expertise with focus on smart linker technology | TA2: Abscopal Treatment Planning System |
| Naser Darwish | Detect Imaging | naser.darwish@gmail.com | Chicago, IL | Detectotherapy has developed integrated PET-radiotherapy platforms enabling real-time tumor visualization and dose verification using dual-ring and flat-panel PET, including tracer-free proton activation imaging. In collaboration with UChicago, UW Madison, and Northwestern, we extend this to FLASH and immuno-radiotherapy workflows, supporting precise dose delivery, abscopal response monitoring, and system-level integration for next-generation universal radiotherapy platforms. | We seek partners in immuno-oncology, biomaterials (smart radiotherapy agents), and FLASH radiobiology to complement our strengths in radiotherapy system integration and real-time imaging. Ideal collaborators bring capabilities in tumor microenvironment modulation, systemic response evaluation, and translational clinical studies to enable development of an integrated, scalable platform for universal radiotherapy. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Clincy Cheung | DropletPharma Corp. | info@dropletpharma.com | Los Angeles, CA | We develop radiolabeling, quantitative imaging, and dosimetry systems that make advanced therapeutics trackable, measurable, and optimizable in vivo. Our work integrates chemistry, imaging, and data to enable real-time localization, retention profiling, and treatment-response feedback for radiotherapeutics and smart biomaterials. | We seek partners developing smart radiotherapy biomaterials, immunomodulatory therapies, and radiotherapy delivery systems. We aim to integrate radiolabeling, imaging, and dosimetry to enable precise tracking, treatment planning, and closed-loop optimization of therapeutic distribution, retention, and response. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Sarah Deek | Sarah Deek | Sarahdeek@utexas.edu | Lake Jackson, TX | Optimizing Water Splitting Reactions in Medical and Industrial Applications | Interdisciplinary thinkers, that’s motivated through an expert level specialty in their domain. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| VERONIKA MAGDANZ | University of Waterloo | veronika.magdanz@uwaterloo.ca | Waterloo, Ontario, Canada | targeted active delivery with high contrast microrobots | immunotherapy experts | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Hem D Shukla | University of Maryland, School of Medicine | hdshukla@som.umaryland.edu | Baltimore, MD | We are employing animal and patients derived tumor organoid models to study better tumor control, normal tissue damage and immune response using electron-FLASH and proton-FLASH radiation. We are also developing nano radiation technologies to induce robust immune response and better tumor control. We have strong expertise in developing AI based machine algorithm to predict treatment response and resistance to therapies. We have adapted precision radiation approach to treat patients. | We are looking forward to team up with experts in the field of immunotherapy, nanotechnology, and precision imaging. We will study flash-RT induced immune response in humanized animal model and patients tissues derived tumor organoids. We will also study flash radiation induced enhancement effect using biodegradable nanoparticles. We also study fluorescence based imaging using nanoparticles which will image distant unirradiated tumor and that will help studying abscopal effect. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Stefanie Eichner | FDNA Inc. | stefanie@fdna.com | Atlanta, GA | FDNA develops AI-driven image and multimodal analytics for phenotype analysis. For this opportunity, FDNA’s relevant focus is longitudinal analysis of ocular, dermatologic, facial, and other visible soft-tissue changes during cancer therapy, with the goal of generating non-invasive monitoring signals that can support treatment-response assessment, toxicity tracking, recovery monitoring, and scalable follow-up outside specialized centers. | FDNA seeks partners in FLASH radiotherapy, smart radiotherapy biomaterials, and AI-driven treatment planning who want to pair core treatment innovation with scalable patient monitoring. As subawardee, FDNA contributes longitudinal image-based visible-phenotype analysis for response, toxicity, and recovery, giving partners a differentiated follow-up layer that can increase translational value, support broader deployment, and improve the overall attractiveness of the team’s solution. | TA2: Abscopal Treatment Planning System |
| Judee Sharon | KuriBio | judee@kuribio.com | Berkeley, CA | KuriBio is developing a liposomal targeting platform for cell-specific delivery across diverse tissues. Our particles use combinatorial surface ligands and can carry multiple payload types, including contrast agents, radiotherapies, proteins, DNA, and RNA. The platform improves targeting specificity, reduces off-target toxicity, and enhances the safety profile for cancer therapies. | We seek partners with payload, radiotherapy, and adjuvant expertise. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Amit Khandhar | HDT Bio | amit.khandhar@hdt.bio | Seattle, WA | HDT Bio’s LION nanoparticle is a clinical-stage nucleic acid delivery platform directly aligned with TA1 of the 1-CURE program. LION enables delivery of our proprietary RIG-I/TLR3 molecular adjuvants and replicon RNA encoding genetic adjuvants, which activate immune pathways that drive potent anti-tumor response while simultaneously activating tumor-specific effector T cells. Our first-gen LION platform also incorporates MRI contrast agents to enable image-guided precision radiotherapy. | HDT seeks a TA2 partner to build an abscopal treatment planning system that leverages its TA1 LION nanoparticle platform, integrating radiotherapy parameters with SRB-driven immune activation. The partner would apply AI/ML and data integration to model, predict, and optimize systemic anti-tumor responses, enabling effective treatment of both primary tumors and distal metastases. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Margie Sutton | UT MD Anderson Cancer Center | mnsutton@mdanderson.org | Houston, TX | Our research group leverages molecular imaging and systems biology approaches to drive therapeutic discovery for applications across inflammation and cancer. Using an iterative approach with a multidisciplinary team we have successfully developed radiopharmaceuticals, therapeutic antibodies and molecular imaging probes for clinical translation, and aim to leverage these interventions and imaging applications to enhance radiotherapy through immune reprogramming. | We have developed a library of immune-reprogramming biologics that would be amenable to nanoparticle based delivery. We are seeking partners with SRBs looking to enhance their immune priming potential. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Tobias Funk | Triple Ring Technologies | tfunk@tripleringtech.com | Newark, CA | Triple Ring Technologies is a leading partner in developing science-driven products in medtech and life sciences. Our interdisciplinary team (30% PhDs) excels in advancing technologies to FDA approval while working with academic partners. We won ARPA-H awards as sub and multiparty. We offer capabilities in simulating and measuring dose in phantoms and anatomical models, developing FDA-approved treatment planning algorithms, software and GUI development, and project management. ISO 13485 cert. | We partner with innovators to solve tough problems and create new businesses. From concept to FDA submission and commercialization, we handle technology development and redesign, as well as complex system integration. We are looking for teaming partners that could use our expertise in radiation therapy while navigating the FDA regulatory pathway. We have acted as primary, subcontractor, or vendor on previous submissions. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Justin Zimmerman | Tempus AI, Inc. | justin.zimmerman@tempus.com | Chicago, IL | Tempus AI specializes in thehigh-dimensional omics (single-cell, spatial, whole-transcriptome) and AI-driven predictive modeling. Our focus is quantifying the tumor microenvironment to identify real-time biomarkers of immune activation. We provide the computational and biological "intelligence layer" for precision oncology, translating complex molecular shifts into actionable treatment insights. For 1-CURE, we offer an AI-ready platform to model abscopal response and optimize treatment planning. | We seek partners in Technical Area 1 (TA1) developing novel "Smart Radiotherapy Biomaterials" (SRBs) and injectable immunoadjuvants. We aim to integrate our Omics/AI modeling suite with your hardware to meet the TA2 "Abscopal Treatment Planning System" requirements. | TA2: Abscopal Treatment Planning System |
| Spencer Lynn | Charles River Analytics, a GRVTY Company | slynn@cra.com | Cambridge, MA | We specialize in highly performant hybrid neuro-symbolic AI for planning and course of action (COA) generation and evaluation, and learning of surrogate/reduced-order models from simulators, such as a high-fidelity radiation–immunology digital twin. These technologies are ideal for clinical decision-aiding, where actions and observations vary by patient, context, and time. We also have AI/ML and engineering experience in biomedical research, signal-processing, and UX development. www.cra.com. | We seek to join a team to bring our neuro-symbolic technologies and human-centered design approach to the TA2 solution as part of an interdisciplinary team with the necessary clinical and bioengineering expertise. We have extensive experience participating in and/or managing large multi-partner programs with ARPA-H, DARPA, IARPA, and others. | TA2: Abscopal Treatment Planning System |
| Chang Chang | UCSD | chang2@ucsd.edu | San Diego, CA | Our group develops human-centered, AI-enabled systems for autonomous radiotherapy treatment planning. We’ve published our framework in Med Phys and Red Journal combining deep learning, dose prediction, automated objective adjustment, and iterative optimization. This foundation aligns with TA2, and its optimization engine, automation logic, and user-facing architecture can be readily extended into an ATPS by incorporating immune-response models, QA, visualization, and hypothesis testing. | I am seeking TA1 partners with expertise in immunogenic nanoparticles, smart radiotherapy biomaterials, and experimental immuno-oncology. I am especially interested in collaborators who can design image-visible, immune-stimulating biomaterials with controlled delivery and generate data for ATPS validation. My group would lead autonomous planning and computational integration, while TA1 partners would lead biomaterial innovation and experimental testing. | TA2: Abscopal Treatment Planning System |
| Liangcai Gu | University of Washington | gulc@uw.edu | Seattle, WA | We develop spatial and multimodal omics methods to map tumor-immune microenvironments and treatment response in tissue. Current work includes high-resolution spatial RNA+protein profiling, primary/metastatic tumor analysis, biomarker discovery, and quantitative integration of pathology and omics into AI-ready features for radiotherapy and immunotherapy studies. | We seek partners in FLASH radiotherapy/medical physics, smart radiotherapy biomaterials, immuno-oncology, animal models of local/metastatic disease, and translational radiation oncology. We are best positioned as a TA2 biology/omics partner generating and integrating spatial/multimodal datasets from primary and metastatic tumors for ATPS training, biomarker discovery, and response validation. | TA2: Abscopal Treatment Planning System |
| Amit Joshi | Medical College of Wisconsin | ajoshi@mcw.edu | Milwaukee, WI, WI | TA1: Published studies on gold and lipid nanoparticle radiosensitizers with CT and MRI image contrast. Pre-clinical models and innovative clinical trials in pancreatic adenocarcinoma and other cancers. TA2: Working novel radiation treatment planning software incorporating immunologic parameters of radiation sensitivity, readily adaptable to model abscopal interactions, FLASH, and nanoparticle radiosensitization. Pre-clinical and clinical proton FLASH capability (Mevion with FLASH kit). | Groups with a) deep GLP and GMP capability needed for nanoparticle scale-up and IND-enabling studies through early phase clinical trial implementation; b) state-of-the-art immune adjuvants including nanoparticle formulations and validated immunomonitoring assays; and c) a seasoned verification and validation team experienced in regulatory-grade clinical implementation of treatment planning software. We are eager to engage industry partners with complementary expertise in any of these capacities. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Katie Kugler | Vivid BioInnovations | KKugler@vivid-bio.com | San Francisco, CA | Our organization develops molecular sensing, microfluidic assay, and computational modeling platforms for adaptive cancer therapy. For 1-CURE, we focus on closed-loop radiotherapy that measures ctDNA, cytokines, and immune activation markers after each fraction, then uses predictive models to optimize dose, fractionation, targeting, and timing of adjunctive immunomodulatory biomaterials. | We seek partners in FLASH-RT, radiation oncology, medical physics, animal tumor models, and immuno-oncology to co-develop and validate an abscopal treatment planning system. Ideal teammates bring access to radiotherapy platforms, preclinical efficacy models, translational and regulatory expertise, imaging and dosimetry, and smart radiotherapy biomaterials or immunoadjuvant delivery technologies. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Charles Apgar | American College of Radiology | capgar@acr.org | The ACR is based in Reston Virginia, but operates without geographic limitations, VA | The American College of Radiology is the only clinical research organization focused specifically on advancing the practice of radiology and radiation oncology with over 50 years of experience developing and conducting clinical trials under sponsorship of the NCI and commercial sponsors. Imaging research has spanned all imaging modalities and diseases and leverages the ACR's informatics infrastructure to facilitate both centralized and federated image analytics. | The ACR collaborates with the premier scientific research group in radiation therapy, the Radiation Therapy Oncology Group (RTOG). We propose partnering with SRB developers to validate performance in multicenter clinical trials leading to commercialization efforts and partnering with TA2 performers to assess abscopal effect. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Clemens Grassberger | University of Washington / Fred Hutch | clemensg@uw.edu | Seattle, WA | Immunological Effects of FLASH, particularly lymphocyte sparing and increased efficacy of IO/FLASH combinations; furthermore we developed computational models to simulate the trafficking of lymphocytes between tumor and draining lymph nodes, fitted to preclinical data | We have extensive FLASH capabilities: 2 experimental proton setups (one clinical, one preclinical) with different beam time structures and energies - great for testing robustness of results; we'd like to be part of a promising team that needs more experimental capability and more immunological and computational focus, which are our strengths | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Prakash Nallathamby | Berthiaume Institute for Precision Health / University of Notre Dame | prakash.d.Nallathamby.1@nd.edu | Notre Dame, IN | The PD[N]ano Lab at Notre Dame develops modular Smart Radiotherapy Biomaterials (SRBs) using magnetoelectric silica nanoparticles (MagSiNs). We focus on magnetoelectrically localizing systemic probes to tumors for precise, image-guided delivery of radioligands and immunoadjuvants. Our research addresses critical toxicity and delivery hurdles in TNBC, ovarian, and prostate cancers, achieving significant tumor inhibition while eliminating cardiotoxicity and neuropathy. | Gemini said PD[N]ano Lab seeks partners in AI-driven treatment planning to optimize dosing and localization. We require expertise in advanced image-guided therapy systems to integrate our contrast-sensitive MagSiN probes. If you have algorithms for real-time therapy mapping, we provide the modular hardware for precision delivery. We also seek clinical and regulatory partners to help transition our validated in vivo success into human-centric 1-CURE curative solutions. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Amit Sawant | University of Maryland | asawant@som.umaryland.edu | Baltimore, MD | Proton and photon FLASH RT, preclinical small and large animal models (mice, pigs, NHPs), immune response modeling, AI, treatment planning, SRB-based clinical trials | Looking for SRB developers with expertise in the radiation oncology space, Preference for platforms that are in or close to early or late phase clinical trials | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Ming-Chung Jiang | Targetrust Biotech. | jiangmwd@gmail.com | Taipei, Taiwan | We developed the world’s only universal tumor-specific target to develop a single, fast, low-cost radiotherapy approach to treat both local and metastatic cancers in all cancer types in all cancer patients. The universal tumor-specific target can be used to produce multifunctional immune-boosting smart radiotherapy biomaterials (SRBs) and to establish AI-driven treatment planning systems. The IVIS imaging showed antibody-Qdots specifically target tumor and not bind to any normal tissue. | 1. Expert in producing multifunctional immune-boosting smart radiotherapy biomaterials (SRBs). 2. Expert in establishing AI-driven treatment planning systems. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Kaushal Rege | Arizona State University | rege@asu.edu | Tempe, AZ | 1. Gel and liquid Nanosensors for ionizing radiation including X-Ray, proton, electron radiotherapy, 2. Biomaterials and nanoparticles 3. Lipopolymer drug delivery systems | broader network including industry partners | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Amberlie Clutterbuck | The Emmes Company | aclutterbuck@emmes.com | Rockville, MD | Emmes is a technology, AI-enabled CRO with 50 years’ experience designing and running complex oncology trials in early- and late-phase development. Our clients include NIH (including NCI Clinical Trials Information Management Systems and Clinical Trials Reporting Program), AIDS Malignancy Consortium, and biotech and pharmaceutical sponsors and foundations, including Bristol-Myers Squibb, Genmab, the Translational Breast Cancer Research Consortium, and the Prostate Cancer Foundation. | Emmes is looking to partner with BioPharma companies, academia, and others that will need CRO support in Phase III for early-stage clinical trials. We are looking for agile partners that are ready to meet the demands of the ARPA-H dynamic environment. Emmes can provide full service CRO and clinical technology and digital AI support including clinical trial protocol development and AI reporting with the exception of regulatory support. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Srivalleesha Mallidi | Tufts University | Srivalleesha.Mallidi@tufts.edu | Boston, MA, MA | Ultrasound Imaging, Biomedical Optics, Optical imaging, photoacoustic imaging, imaging guided therapies, light and sound based therapies, personalized treatments, AI-based treatments, smart nanomaterials | Radiologists, flash radiotherapy specialists | TA2: Abscopal Treatment Planning System |
| Ulas Bagci | Northwestern University | ulas.bagci@northwestern.edu | Chicago, IL | Machine and Hybrid Intelligence Lab (Bagci Lab) is an AI research lab focused on advancing radiologic imaging analysis, segmentation, prediction, and multimodal data integration for cancer and other complex diseases. Our team develops computational methods that learn from medical images and complementary data streams to generate clinically meaningful insight for diagnosis, risk stratification, treatment planning, response assessment, and longitudinal outcome prediction. | Our organization is seeking clinical, translational, and technical teaming partners whose work would be strengthened by advanced AI expertise in imaging and multimodal data analysis. As an AI lab, we are particularly interested in collaborating with radiation oncology groups, cancer centers, medical physicists, immunologists, and biomaterial researchers and industry teams for developing next-generation radiotherapy approaches. | TA2: Abscopal Treatment Planning System |
| Stephen Kron | University of Chicago | sjkron@gmail.com | Chicago, IL | Immunoradiotherapy | FLASH expertise | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Edina Zsigmond | Curesign Ltd | edina@nacrecapital.com | Kiryat Ono | Curesign develops an AI-driven, software-based platform combining 3D B-mode ultrasound and elastography for objective, real-time assessment of tumor response. By transforming ultrasound into a quantitative biomarker, we detect treatment response or resistance within 2–4 weeks or less. Our platform provides automated tumor segmentation, stiffness mapping, and longitudinal comparisons to guide adaptive therapy in human clinical settings, currently focusing on breast, pancreatic, and liver cancers. | Within a 1-CURE consortium Curesign offers to -Support early‑phase human studies (breast or other solid tumors) by providing structured, quantitative local response assessments as part of the clinical protocol -Provide software tools and AI models for automated tumor segmentation and longitudinal comparison of ultrasound scans -Deliver early response metrics (e.g., stiffness change, volumetric change) that can be integrated into the consortium’s statistical/AI models and clinical decision | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |
| Paul Segars | Duke University Center for Virtual Imaging Trials | paul.segars@duke.edu | Durham, NC | CVIT focuses on digital twin–based simulation of anatomy, disease, imaging, and therapy to enable in silico clinical trials. We develop population-scale phantoms, imaging and radiation transport models, and AI-driven evaluation tools to optimize detection, treatment planning, and therapy response across diverse patient populations. | We seek partners in radiotherapy biomaterials and AI-driven treatment planning and delivery systems. We also welcome collaborators in tumor immunology and clinical oncology. Ideal partners bring therapeutic, biological, or clinical capabilities that integrate with our digital twin platform to enable system-level simulation, validation, and optimization of cancer therapies. | TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials, TA2: Abscopal Treatment Planning System |
| Fiona Ginty | GE HealthCare | Fiona.ginty@gehealthcare.com | Niskayuna, NY | 2) Imaging and software solutions for RT planning, measuring therapy response and RT workflow planning; 2) Spatial imaging tools for spatially quantifying immune response to RT in intact formalin fixed tumors. | Interested in partnering with SRB domain experts and clinical trial sites . | TA2: Abscopal Treatment Planning System |
| Evgeny Galyaev | Radiation Detection and Imaging (RDI) Technologies | egalyaev@radiationimaging.com | Phoenix, AZ | RDI develops precision radiation measurement and verification systems for advanced cancer radiotherapy. Current focus areas include high-speed, high-resolution detector arrays for proton, heavy-ion, and FLASH radiotherapy QA; beam and dose imaging; treatment-delivery verification; scalable data acquisition electronics; reconstruction/AI algorithms; and clinically integrated software/data workflows for safer, more precise treatment planning and validation. | RDI seeks teaming partners in FLASH radiobiology, tumor immunology, smart radiotherapy biomaterials, AI-driven treatment planning, and translational/preclinical oncology. We are especially valuable to teams needing rigorous radiation measurement, dosimetry, delivery verification, QA workflow design, detector integration, and clinically relevant data generation to support treatment optimization, validation, and abscopal-response modeling. | TA2: Abscopal Treatment Planning System, TA1: Immunogenic Nanoparticle Smart Radiotherapy Biomaterials |